Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Sep;24(3):343–349. doi: 10.1111/j.1365-2125.1987.tb03179.x

Post marketing surveillance of captopril (for hypertension): a preliminary report.

D Chalmers 1, S L Dombey 1, D H Lawson 1
PMCID: PMC1386256  PMID: 3311104

Abstract

1 The methodology and interim results of a post marketing surveillance of captopril, the first orally active angiotensin converting enzyme inhibitor are presented. 2 Utilising viewdata technology, details of hypertensive patients were entered directly into a mainframe computer. This allowed day to day monitoring of events; a facility not available with paper-based methods. 3 The design of the study allowed analysis of results including some details of efficacy, concomitant therapy, any disease symptoms and reasons for withdrawal. These factors could be categorised according to sex and age. 4 This preliminary report is based on the first 13,295 patients entered from July 1983 with follow-up until January 1985. The results of the study confirm the safety of captopril in the patients studied.

Full text

PDF
349

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colin Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med. 1985 Mar;54(215):253–268. [PubMed] [Google Scholar]
  2. Colin-Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. Br Med J (Clin Res Ed) 1982 Nov 6;285(6351):1311–1313. doi: 10.1136/bmj.285.6351.1311. [DOI] [PubMed] [Google Scholar]
  3. Colin-Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J (Clin Res Ed) 1983 May 28;286(6379):1713–1716. doi: 10.1136/bmj.286.6379.1713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Colin-Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up. Br Med J (Clin Res Ed) 1985 Oct 19;291(6502):1084–1088. doi: 10.1136/bmj.291.6502.1084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Croog S. H., Levine S., Testa M. A., Brown B., Bulpitt C. J., Jenkins C. D., Klerman G. L., Williams G. H. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986 Jun 26;314(26):1657–1664. doi: 10.1056/NEJM198606263142602. [DOI] [PubMed] [Google Scholar]
  6. Dollery C. T., Rawlins M. D. Monitoring adverse reactions to drugs. Br Med J. 1977 Jan 8;1(6053):96–97. doi: 10.1136/bmj.1.6053.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Edwards C. R., Padfield P. L. Angiotensin-converting enzyme inhibitors: past, present, and bright future. Lancet. 1985 Jan 5;1(8419):30–34. doi: 10.1016/s0140-6736(85)90975-4. [DOI] [PubMed] [Google Scholar]
  8. Ferguson R. K., Turini G. A., Brunner H. R., Gavras H., McKinstry D. N. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977 Apr 9;1(8015):775–778. doi: 10.1016/s0140-6736(77)92958-0. [DOI] [PubMed] [Google Scholar]
  9. Harcus A. W., Ward A. E., Smith D. W. Methodology of monitored release of a new preparation: buprenorphine. Br Med J. 1979 Jul 21;2(6183):163–165. doi: 10.1136/bmj.2.6183.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Inman W. H. Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton. Br Med J (Clin Res Ed) 1981 Apr 11;282(6271):1216–1217. doi: 10.1136/bmj.282.6271.1216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lawson D. H., Henry D. A. Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J. 1977 Mar 12;1(6062):691–692. doi: 10.1136/bmj.1.6062.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Maclay W. P., Crowder D., Spiro S., Turner P. Postmarketing surveillance: practical experience with ketotifen. Br Med J (Clin Res Ed) 1984 Mar 24;288(6421):911–914. doi: 10.1136/bmj.288.6421.911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shapiro S., Siskind V., Slone D., Lewis G. P., Jick H. Drug rash with ampicillin and other penicillins. Lancet. 1969 Nov 8;2(7628):969–972. doi: 10.1016/s0140-6736(69)90535-2. [DOI] [PubMed] [Google Scholar]
  14. Wilson A. B. Post-marketing surveillance of adverse reactions to new medicines. Br Med J. 1977 Oct 15;2(6093):1001–1003. doi: 10.1136/bmj.2.6093.1001. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES